ES2447815T3 - Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor - Google Patents

Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor Download PDF

Info

Publication number
ES2447815T3
ES2447815T3 ES10012043.5T ES10012043T ES2447815T3 ES 2447815 T3 ES2447815 T3 ES 2447815T3 ES 10012043 T ES10012043 T ES 10012043T ES 2447815 T3 ES2447815 T3 ES 2447815T3
Authority
ES
Spain
Prior art keywords
aliphatic compound
gen
optionally substituted
cycloaliphatic group
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10012043.5T
Other languages
English (en)
Inventor
Hans Prof. Dr. Schick
Robert Dr. Frank
Melanie Dr. Reich
Ruth Dr. Jostock
Gregor Dr. Bahrenberg
Fritz Dr. Theil
Brigitta Dr. Henkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2447815T3 publication Critical patent/ES2447815T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos espiro sustituidos de fórmula general I **Fórmula** donde m es 0, 1, 2, 3 o 4, n es 1, R1 representa un grupo -C(>=S)-NR8R9; o, cuando m es distinto de 0 y/o R5 es distinto de H, además un grupo -C(>=O)-NR6R7; R2 representa un grupo alifático lineal o ramificado, saturado o insaturado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro de la cadena; donde los sustituyentes de los grupos alifáticos se pueden seleccionar independientemente de entre el grupo consistente en F, Cl, Br, I, -CN, -NO2, -OH, -SH y -NH2; un grupo cicloalifático saturado o insaturado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro del anillo, en caso dado unido mediante un grupo alquileno, alquenileno o alquinileno, lineal o ramificado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo como miembro de la cadena y/o condensado con un sistema de anillo mono- o poli-cíclico, no sustituido o al menos monosustituido; o un grupo arilo o heteroarilo no sustituido o al menos monosustituido, en caso dado unido mediante un grupo alquileno, alquenileno o alquinileno, lineal o ramificado, no sustituido o al menos monosustituido, en caso dado incluyendo un heteroátomo en la cadena, y/o condensado con un sistema de anillo mono- o poli-cíclico, no sustituido o al menos monosustituido.
ES10012043.5T 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor Active ES2447815T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005023784 2005-05-19
DE102005023784A DE102005023784A1 (de) 2005-05-19 2005-05-19 Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
ES2447815T3 true ES2447815T3 (es) 2014-03-13

Family

ID=36646208

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06742950T Active ES2370038T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su uso para la preparación de medicamentos contra el dolor.
ES10012043.5T Active ES2447815T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su utilización para la preparación de medicamentos contra el dolor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES06742950T Active ES2370038T3 (es) 2005-05-19 2006-05-17 Compuestos espiro sustituidos y su uso para la preparación de medicamentos contra el dolor.

Country Status (13)

Country Link
US (1) US20080214807A1 (es)
EP (2) EP2292625B1 (es)
JP (1) JP5376941B2 (es)
AT (1) ATE524478T1 (es)
CA (1) CA2608385A1 (es)
CY (1) CY1112137T1 (es)
DE (1) DE102005023784A1 (es)
DK (1) DK1893620T3 (es)
ES (2) ES2370038T3 (es)
PL (2) PL2292625T3 (es)
PT (1) PT1893620E (es)
SI (1) SI1893620T1 (es)
WO (1) WO2006122769A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US8927715B2 (en) * 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
JP5451646B2 (ja) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（カルボキシメチル）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
EP3722284B1 (en) 2016-01-13 2025-01-22 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527513A (ja) * 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
CA2328414C (en) * 1998-05-08 2014-04-15 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003099284A1 (en) * 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
ATE524478T1 (de) 2011-09-15
WO2006122769A2 (de) 2006-11-23
EP2292625A1 (de) 2011-03-09
EP1893620B1 (de) 2011-09-14
WO2006122769A3 (de) 2007-03-15
CA2608385A1 (en) 2006-11-23
US20080214807A1 (en) 2008-09-04
PL2292625T3 (pl) 2014-04-30
PT1893620E (pt) 2011-10-31
JP2008540592A (ja) 2008-11-20
ES2370038T3 (es) 2011-12-12
EP2292625B1 (de) 2013-12-25
DK1893620T3 (da) 2012-01-16
SI1893620T1 (sl) 2012-04-30
PL1893620T3 (pl) 2012-02-29
JP5376941B2 (ja) 2013-12-25
EP1893620A2 (de) 2008-03-05
CY1112137T1 (el) 2015-11-04
DE102005023784A1 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
CY1112137T1 (el) Υποκατεστημενες σπειρο-ενωσεις και η χρηση αυτων για παραγωγη φαρμακευτικων μεσων εναντι πονου
AU2011215704B2 (en) Secondary structure stabilized NMDA receptor modulators and uses thereof
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
WO2007091948A3 (en) Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1
WO2004014902A8 (en) Compounds having an activity at metabotropic glutamate receptors
SE9904508D0 (sv) New compounds
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
ATE326453T1 (de) Antithrombotische amide
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
SI1910381T1 (sl) Substituirane spojine 1-oksa-3,8-diazaspiro(4,5)-dekan-2-on in njihova uporaba za pripravo zdravil
Wrobleski et al. Cyclobutane derivatives as potent NK1 selective antagonists
SE0102055D0 (sv) New Compounds
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
CY1110613T1 (el) Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
DE60309324D1 (de) Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
DE60137451D1 (de) N-substituierte Amide als NK1 Rezeptor Antagonisten
TW200621223A (en) Acyclic 1,3-diamines and uses therefor